返回 
加入收藏
双歧杆菌三联活菌胶囊联合大黄赤芍汤对肝硬化患者内毒素血症及肠黏膜屏障功能的影响
x
请在关注微信后，向客服人员索取文件
| 篇名： | 双歧杆菌三联活菌胶囊联合大黄赤芍汤对肝硬化患者内毒素血症及肠黏膜屏障功能的影响 |
| TITLE： | |
| 摘要： | 目的：探讨双歧杆菌三联活菌胶囊联合大黄赤芍汤对肝硬化患者内毒素血症及肠黏膜屏障功能的影响。方法：90例肝硬化患者按照随机数字表法分为中西医组和西医组，各45例。两组患者均予以保肝利尿、降低门脉压和营养支持等对症治疗。在此基础上，西医组患者予以双歧杆菌三联活菌胶囊0.42 g，tid，po；中西医组患者在西医组治疗基础上加用大黄赤芍汤口服，每天1剂，两组均连用6周。观察并记录两组患者治疗前后肝功能指标与血清内毒素（ET）、降钙素原（PCT）和二胺氧化酶（DAO）水平。结果：治疗6周后，两组患者血清丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）、总胆红素（TBIL）、ET、PCT和DAO水平均较治疗前明显下降，差异有统计学意义（P＜0.05或P＜0.01），且中西医组下降幅度明显大于西医组，差异有统计学意义（P＜0.05）。结论：双歧杆菌三联活菌胶囊联合大黄赤芍汤治疗肝硬化患者，能降低血清ALT、AST和TBIL水平，保护患者肝功能；还能降低血清ET、PCT和DAO水平，减轻内毒素血症，保护与修复肠黏膜屏障功能。 |
| ABSTRACT： | OBJECTIVE： To discuss effects of Bifid triple viable capsules combined with Dahuang chishao decoction on endotoxemia and intestinal mucosal barrier function of patients with hepatocirrhosis. METHODS： 90 patients with hepatocirrhosis were randomly divided into traditional Chinese and western medicine group and western medicine group with 45 cases in each group. Both groups were given symptomatic treatment， such as liver protection and diuresis， lowering portal pressure and nutrition support. Based on this， western medicine group was given Bifid triple viable capsules 0.42 g， tid， po； traditional Chinese and western medicine group was additionally given Dahuang chishao decoction orally， one dose a day， on the basis of western medicine group. Both 2 groups were treated for 6 weeks. The changes of liver function index， serum endotoxin （ET）， procalcitonin （PCT） and diamine oxidase （DAO） levels of patients were observed and recorded in 2 groups before and after treatment. RESULTS： After 6 weeks treatment， serum ALT， AST and TBIL， ET， PCT and DAO levels of patients in 2 groups declined significantly， compared with before treatment， with statistical significance （P＜0.05 or P＜0.01）； the decrease of traditional Chinese and western medicine group was more significant than western medicine group， with statistical significance （P＜0.05）. CONCLUSIONS： Bifid triple viable capsules combined with Dahuang chishao decoction can reduce ALT， AST and TBIL levels in patients with hepatocirrhosis， protect liver function； reduce serum ET， PCT and DAO levels， release endotoxemia， and protect and remedy intestinal mucosal barrier function. |
| 期刊： | 2016年第27卷第5期 |
| 作者： | 卜仁梅，傅石明 |
| AUTHORS： | BU Renmei，FU Shiming |
| 关键字： | 肝硬化；双歧杆菌三联活菌胶囊；大黄赤芍汤；内毒素血症；肠黏膜屏障功能 |
| KEYWORDS： | Hepatocirrhosis； Bifid triple viable capsules； Dahuang chishao decoction； Endotoxemia； Intestinal mucosal barrier function |
| 阅读数： | 278 次 |
| 本月下载数： | 1 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
